Pure Biologics SA (PL:PUR)
FRANKFURT:PUR
PUR Stock Chart & Stats
zł2.16
-zł0.04(-1.82%)
―
--
Day’s Range― - ―
52-Week Rangezł1.35 - zł6.63
Previous CloseN/A
VolumeN/A
Average Volume (3M)288.38K
Market Cap
zł26.45M
Enterprise Valuezł30.84M
Total Cash (Recent Filing)zł1.02M
Total Debt (Recent Filing)zł14.40M
Price to Earnings (P/E)―
Beta-0.87
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.45
Shares Outstanding12,244,716
10 Day Avg. Volume14,345
30 Day Avg. Volume288,380
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)-1.24
Price to Sales (P/S)0.00
P/FCF Ratio-2.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PUR FAQ
What was Pure Biologics SA’s price range in the past 12 months?
Pure Biologics SA lowest stock price was zł1.35 and its highest was zł6.63 in the past 12 months.
What is Pure Biologics SA’s market cap?
Pure Biologics SA’s market cap is zł26.45M.
When is Pure Biologics SA’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Pure Biologics SA’s earnings last quarter?
Currently, no data Available
Is Pure Biologics SA overvalued?
According to Wall Street analysts Pure Biologics SA’s price is currently Undervalued.
Does Pure Biologics SA pay dividends?
Pure Biologics SA does not currently pay dividends.
What is Pure Biologics SA’s EPS estimate?
Pure Biologics SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pure Biologics SA have?
Pure Biologics SA has 12,244,716 shares outstanding.
What happened to Pure Biologics SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Pure Biologics SA?
Currently, no hedge funds are holding shares in PL:PUR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pure Biologics SA
Pure Biologics Spólka Akcyjna operates as a biopharmaceutical enterprise, concentrating its efforts on the discovery and development of novel biological pharmaceuticals and targeted, non-systemic treatments. The company's key therapeutic interests span immuno-oncology, various autoimmune conditions, and rare diseases. Its capabilities encompass the entire process for antibodies and aptamers, from their initial creation and purification to detailed analysis and characterization. Additionally, Pure Biologics is skilled in the design, development, and rigorous validation of diagnostic and research assays, while also advancing technology platforms for the precise selection of active therapeutic molecules. A significant offering is PureApta, a adaptable platform engineered for the in vitro selection of modified aptamers, suitable for both medical treatment and diagnostic applications. The firm is also actively pursuing the development of localized therapies aimed at assisting individuals afflicted by neurological autoimmune disorders, including conditions like neuromyelitis optica and myasthenia gravis. Founded in 2010, Pure Biologics Spólka Akcyjna is headquartered in Wroclaw, Poland.